Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Conference Call November 21, 2022 4:30 PM ET

Company Participants

Jennifer Viera - Senior Director, Investor Relations & Corporate Communications

Jay Luly - President & Chief Executive Officer

Paul Mellett - Chief Financial Officer

Tara Kieffer - Senior Vice President, New Product Strategy & Development

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Yasmeen Rahimi - Piper Sandler

Brian Skorney - Baird

Liisa Bayko - Evercore ISI

Eric Joseph - JPMorgan

Roanna Ruiz - SVB Securities

Jay Olson - Oppenheimer

Roy Buchanan - JMP Securities

Operator

Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Full Year Ended September 30, 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded.

I’d now like to hand the call over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal fourth quarter and full year 2022 financial results was issued this afternoon and is available on our website. On the call today are Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-Q and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone. At Enanta, we are leveraging our expertise in medicinal chemistry, virology and preclinical sciences to discover new compounds that can be developed into groundbreaking medicines. Our fiscal fourth quarter, as well as 2022 overall was a year of progress toward this effort. With multiple ongoing and planned clinical studies across our pipeline, we are poised to execute on our vision to transform the lives of patients with curative therapies, building on our prior success in hepatitis C.